These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 17238194)
1. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. Deng R; Balthasar JP J Pharm Sci; 2007 Jun; 96(6):1625-37. PubMed ID: 17238194 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. Hansen RJ; Balthasar JP J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Teeling JL; Jansen-Hendriks T; Kuijpers TW; de Haas M; van de Winkel JG; Hack CE; Bleeker WK Blood; 2001 Aug; 98(4):1095-9. PubMed ID: 11493456 [TBL] [Abstract][Full Text] [Related]
4. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Hansen RJ; Balthasar JP Blood; 2002 Sep; 100(6):2087-93. PubMed ID: 12200371 [TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Hansen RJ; Balthasar JP Thromb Haemost; 2002 Dec; 88(6):898-9. PubMed ID: 12529736 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Song S; Crow AR; Freedman J; Lazarus AH Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021 [TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia. Tremblay T; Paré I; Bazin R Transfusion; 2013 Feb; 53(2):261-9. PubMed ID: 22670706 [TBL] [Abstract][Full Text] [Related]
8. Cationized IVIg as a potential substitute to IVIg for the treatment of experimental immune thrombocytopenia. Trépanier P; St-Amour I; Bazin R Int Immunopharmacol; 2013 Aug; 16(4):409-13. PubMed ID: 23665226 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Crow AR; Song S; Siragam V; Lazarus AH Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):710-3. PubMed ID: 16933274 [TBL] [Abstract][Full Text] [Related]
12. Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain. Leontyev D; Neschadim A; Branch DR Transfusion; 2014 Nov; 54(11):2871-9. PubMed ID: 24826802 [TBL] [Abstract][Full Text] [Related]
13. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia. Crow AR; Suppa SJ; Chen X; Mott PJ; Lazarus AH Blood; 2011 Dec; 118(24):6403-6. PubMed ID: 22001393 [TBL] [Abstract][Full Text] [Related]
14. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction. Katsman Y; Foo AH; Leontyev D; Branch DR Transfusion; 2010 Jun; 50(6):1285-94. PubMed ID: 20088841 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. Jin F; Tayab ZR; Balthasar JP AAPS J; 2006 Jan; 7(4):E895-902. PubMed ID: 16594642 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Jin F; Balthasar JP Hum Immunol; 2005 Apr; 66(4):403-10. PubMed ID: 15866704 [TBL] [Abstract][Full Text] [Related]
17. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Bazin R; Lemieux R; Tremblay T; St-Amour I Br J Haematol; 2004 Oct; 127(1):90-6. PubMed ID: 15384982 [TBL] [Abstract][Full Text] [Related]
18. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases. Zhou Z; Qiao Z; Li H; Luo N; Zhang X; Xue F; Yang R Autoimmunity; 2016; 49(1):50-7. PubMed ID: 26525513 [TBL] [Abstract][Full Text] [Related]
19. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295 [TBL] [Abstract][Full Text] [Related]
20. Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia. Smith B; Christodoulou L; Clargo A; Eddleston A; Greenslade K; Lightwood D; Shock A; Tyson K; Brennan FR Int Immunopharmacol; 2019 Jan; 66():362-365. PubMed ID: 30529500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]